Dr Stirling Bryan is a trained economist with a career-long specialization in the economics of health care. His PhD (Economics) was obtained from Brunel University (UK), following a Masters (Health Economics) from the University of York (UK). For over 20 years he has been a university-based practicing health economist with extensive engagement to the policy and decision making world. The vast majority of his career has been spent in the UK, initially in London (appointments at St Thomas’ Hospital Medical School and then Brunel University) and subsequently in Birmingham (senior lecturer and then full professor at the University of Birmingham). He has taught health economics to undergraduate economists and medical trainees, to postgraduate health economics students and to health sector professionals. His research track record reveals a longstanding goal of informing policy and practice. This is demonstrated, in part, through an extensive involvement with the UK National Institute for Health & Clinical Excellence (NICE). For many years he led the University of Birmingham team that conducted economic analyses for NICE, and subsequently served for 3 years as a member of the NICE technology appraisals committee, advising on coverage policy. In 2005 he was awarded a Commonwealth Fund Harkness Fellowship and spent one year in the US, based at Stanford University, researching technology coverage decision making in US health care organisations. His published papers reveal an ongoing research interest in coverage decision making processes. Since his relocation to Canada in 2008 (appointment as full professor in UBC’s School of Population & Public Health, and Director of the Centre for Clinical Epidemiology & Evaluation, VCH Research Institute), he has continued a focus on policy-relevant research. His current position, sponsored by Vancouver Coastal Health, sees him working alongside policy colleagues in one of BC’s largest regional health authorities.
Bryan S, Dormandy E, Roberts T, Ades T, Barton P, Juarez-Garcia A, Andronis L, Karnon J, Marteau TM. The cost-effectiveness of primary care screening for sickle cell and thalassaemia. British Journal of General Practice (in press)
Jowett S, Bryan S, Mant J, Fletcher K, Roalfe A, Fitzmaurice D, Lip GY, Hobbs FD. Cost Effectiveness of Warfarin Versus Aspirin in Patients Older Than 75 Years With Atrial Fibrillation. Stroke. 2011 Apr 21. [Epub ahead of print]
Whitehurst DG, Bryan S, Hay EM, Thomas E, Young J, Foster NE.Cost-effectiveness of acupuncture care as an adjunct to exercise-based physical therapy for osteoarthritis of the knee. Phys Ther. 2011 May;91(5):630-41. Epub 2011 Mar 17.
Whitehurst DG, Bryan S, Hay EM, Thomas E, Young J, Foster NE. Cost-Effectiveness of Acupuncture Care as an Adjunct to Exercise-Based Physical Therapy for Osteoarthritis of the Knee. Phys Ther. 2011 Mar 17. [Epub ahead of print] PMID: 21415230
Whitehurst DG, Bryan S. Another Study Showing that Two Preference-Based Measures of Health-Related Quality of Life (EQ-5D and SF-6D) are not Interchangeable. But why Should we Expect Them to be? Value Health. 2011 Feb 9. [Epub ahead of print] PMID: 21315635
Brealey S, Andronis L, Dennis L, Atwell C, Bryan S, Coulton S, Cox H, Cross B, Fylan F, Garratt A, Gilbert F, Gillan M, Hendry M, Hood K, Houston H, King D, Morton V, Robling M, Russell I, Wilkinson C. Participants’ preference for type of leaflet used to feed back the results of a randomised trial: a survey. Trials. 2010 Dec 1;11:116. PMID: 21122094
Kaambwa B, Bryan S, Gray J, Milner P, Daniels J, Khan KS, Roberts TE. Cost-effectiveness of rapid tests and other existing strategies for screening and management of early-onset group B streptococcus during labour. BJOG. 2010 Dec;117(13):1616-27. doi: 10.1111/j.1471-0528.2010.02752.x. PMID: 21078057
Dormandy E, Gulliford M, Bryan S, Roberts TE, Calnan M, Atkin K, Karnon J, Logan J, Kavalier F, Harris HJ, Johnston TA, Anionwu EN, Tsianakas V, Jones P, Marteau TM. Effectiveness of earlier antenatal screening for sickle cell disease and thalassaemia in primary care: cluster randomised trial. BMJ. 2010 Oct 5;341:c5132. doi: 10.1136/bmj.c5132. PMID: 20923841
McManus RJ, Mant J, Bray EP, Holder R, Jones MI, Greenfield S, Kaambwa B, Banting M, Bryan S, Little P, Williams B, Hobbs FD. Telemonitoring and self-management in the control of hypertension (TASMINH2): a randomised controlled trial. Lancet. 2010 Jul 17;376(9736):163-72. Epub 2010 Jul 8.PMID: 20619448.
Liu-Ambrose T, Eng JJ, Boyd LA, Jacova C, Davis JC, Bryan S, Lee P, Brasher P, Hsiung GY. Promotion of the mind through exercise (PROMoTE): a proof-of-concept randomized controlled trial of aerobic exercise training in older adults with vascular cognitive impairment. BMC Neurol. 2010 Feb 17;10:14.PMID: 20158920.
Bryan S, Jowett S. Hypothetical versus real preferences: results from an opportunistic field experiment. Health Econ. 2009 Nov 27. [Epub ahead of print] PubMed PMID: 19946885.
Jowett S, Bryan S, Poller L, VAN DEN Besselaar AM, VAN DER Meer FJ, Palareti
G, Shiach C, Tripodi A, Keown M, Ibrahim S, Lowe G, Moia M, Turpie AG, Jespersen J. The cost-effectiveness of computer-assisted anticoagulant dosage: results from the European Action on Anticoagulation (EAA) multicentre study. J Thromb Haemost. 2009 Sep;7(9):1482-90. Epub 2009 Jun 8. PubMed PMID: 19515090.
Marshall A, Billingham LJ, Bryan S. Can we afford to ignore missing data in cost-effectiveness analyses? Eur J Health Econ. 2009 Feb;10(1):1-3. PMID: 18936993.
RECRUITING GRADUATE STUDENTS INTERESTED IN:
* Patient-reported outcome measures (PROMs)
* ‘Innovation’ in health care: what does it mean and what utility does the concept have?
* Hypothetical versus real (or stated versus revealed) preferences
* Performance measurement in health care